FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

62 letters match. Newest first.

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  3. Sciarra Aeromed, Inc.

    Sciarra Aeromed's purportedly sterile veterinary drug was contaminated and made under insanitary conditions, FDA says.

    High risk
  4. Fresenius Kabi USA LLC

    FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

    High risk
  5. Celmade

    FDA warned Celmade over websites selling unapproved, misbranded injectable botulinum toxin products to U.S. consumers.

    High risk
  6. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  7. Fresenius Medical Care AG & Co. KGaA

    Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.

    High risk
  8. Eugia Pharma Specialities Limited

    FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.

    High risk
  9. International Medication Systems Limited

    FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.

    High risk
  10. Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com

    FDA warned Pure Arylcyclohexylamine Store it sells unapproved, misbranded ketamine drugs, including an injectable, to U.S. consumers online.

    High risk
  11. Jubilant HollisterStier General Partnership

    FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.

    High risk
  12. ProRx LLC

    ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

    High risk
  13. Par Health USA, LLC & Endo USA, Inc.

    FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.

    High risk
  14. Thrive Health and Wellness, LLC dba Thrive Health Solutions

    FDA warned Thrive Health and Wellness, a Colorado repackager, that sterile drugs were made in unsanitary conditions and sold without approval.

    High risk
  15. Apollo Care, LLC

    FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.

    High risk
  16. Beauty of Aztlan LLC

    FDA warns Beauty of Aztlan it sells unapproved, misbranded injectable botulinum toxin drugs online to U.S. consumers.

    High risk
  17. Lovega LLC dba Pink Pony Peptides

    FDA warned Pink Pony Peptides that its GLP-2 TZ, GLP-3 RT and Bacteriostatic Water are unapproved new drugs sold online.

    High risk
  18. PekCura Labs

    FDA warned PekCura Labs that its GLP-1-S, GLP-2-T, GLP-3-R, and bacteriostatic water products are unapproved new drugs sold online.

    High risk
  19. GenoGenix LLC

    FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.

    High risk
  20. Catalent Indiana, LLC

    Catalent Indiana's Bloomington plant released sterile vials contaminated with mammalian hair and failed to investigate, FDA says.

    High risk
  21. Uriel Pharmacy, Inc.

    Uriel Pharmacy's homeopathic ampule drugs are unapproved new drugs and were made under serious CGMP violations.

    High risk
  22. Korea Filler Experts

    FDA warned Korea Filler Experts that its website sells unapproved and misbranded injectable botulinum toxin drugs, including Nabota 100UI, to U.S. consumers.

    High risk
  23. Dermacare dba Filler Outlet

    South Korea's Dermacare, doing business as Filler Outlet, sells unapproved, misbranded injectable botulinum toxin to U.S. consumers through its website.

    High risk
  24. Maypharm

    Maypharm website sells unapproved, misbranded Botulax botulinum toxin to U.S. consumers, FDA says.

    High risk
  25. Estaderma

    FDA warned South Korea's Estaderma that its website sells unapproved, misbranded injectable botulinum toxin (Liztox) to U.S. consumers.

    High risk
  26. CelestaPro

    FDA told CelestaPro its website sells unapproved, misbranded injectable botulinum toxin drugs, including "Nabota 200 Unit", to U.S. consumers.

    High risk
  27. AceCosm

    AceCosm’s website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers, FDA says.

    High risk
  28. Dermax Co., Ltd

    FDA warned China's Dermax Co., Ltd. over its website selling unapproved, misbranded injectable botulinum toxin to U.S. consumers.

    High risk
  29. Aesthetic Essentials Limited

    Hong Kong company Aesthetic Essentials Limited sells not-FDA-approved, mislabeled injectable botulinum toxin drugs online to U.S. consumers.

    High risk
  30. COSMO KOREA

    FDA told South Korea's COSMO KOREA that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.

    High risk
  31. Glam Derma

    FDA warns Glam Derma over website selling unapproved, misbranded injectable botulinum toxin products.

    High risk
  32. MJS Medicals

    FDA warned South Korea's MJS Medicals for selling unapproved, misbranded botulinum toxin ("Innotox") to U.S. consumers online.

    High risk
  33. Derma Solution

    FDA warned Derma Solution for selling unapproved, misbranded injectable Botulax botulinum toxin drugs online to U.S. consumers.

    High risk
  34. Glowface

    Glowface's website sells unapproved, misbranded injectable Botulax botulinum toxin drugs to U.S. consumers, FDA says.

    High risk
  35. Liebel-Flarsheim Company LLC

    Liebel-Flarsheim's Raleigh, NC sterile drug plant failed to investigate microbial and endotoxin test failures and let cleanrooms and equipment fall into disrepair.

    High risk
  36. cheaptrustedpharmacy.com

    cheaptrustedpharmacy.com sells unapproved, misbranded prescription drugs to U.S. consumers online, FDA warns.

    High risk
  37. Janssen Vaccines Corp., A Johnson & Johnson Company

    FDA warned Janssen Vaccines over inadequate investigations of stopper complaints and missed regulatory notifications for its injection drug.

    Medium
  38. Somerset Therapeutics Private Limited

    FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.

    High risk
  39. Amneal Pharmaceuticals, LLC

    FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.

    High risk
  40. Boothwyn Pharmacy LLC

    FDA warns Boothwyn Pharmacy over unapproved compounded animal drugs and falsified endotoxin records.

    High risk
  41. Exela Pharma Sciences, LLC

    Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.

    High risk
  42. www.buynetmeds.com

    FDA warned www.buynetmeds.com for selling unapproved, misbranded tapentadol and semaglutide drugs, including injectables, to U.S. consumers online.

    High risk
  43. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warns Empower Pharmacy that insanitary conditions in sterile drug compounding put patients at risk.

    High risk
  44. Empower Clinic Services, LLC dba Empower Pharma

    FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.

    High risk
  45. Annovex Pharma, Inc.

    FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.

    High risk
  46. Filler Lux dba Filler Lux USA

    FDA warned Filler Lux USA that it sells unapproved injectable lipolytic drugs online without FDA approval.

    High risk
  47. Fox Pharma LLC

    FDA warned Fox Pharma LLC that it sells unapproved injectable lipolytic drugs online.

    High risk
  48. Hyaluron Pen Store, LLC dba Glow Nest Beauty

    Glow Nest Beauty sells unapproved injectable fat-dissolving drugs online, FDA warned.

    High risk
  49. Julian Naya Beauty LLC

    FDA warned Julian Naya Beauty LLC that it sells six unapproved injectable fat-dissolving drugs on its website and social media.

    High risk
  50. Eugia Pharma Specialities Limited

    FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.

    High risk